MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
A live webcast of the presentation will be available on the InvestorRelations section of MAP Pharmaceuticals' website at http://www.mappharma.com.A replay will also be available within 24 hours for seven days following thepresentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies forchildren and adults who suffer from chronic conditions that it believes arenot adequately treated by currently available medicines. The Company appliesits proprietary inhalation technologies to enhance the therapeutic benefitsand commercial attractiveness of proven drugs while minimizing risk bycapitalizing on their known safety, efficacy and commercialization history.MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004,in late stage development for the potential treatment of pediatric asthma andmigraine respectively. MAP Pharmaceuticals' pipeline also includes a drugcandidate in early clinical development for the treatment of asthma andchronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.
SOURCE MAP Pharmaceuticals, Inc.
You May Also Like